glp-1 news oct 16 2025 in three charts: sticky adoption and what's next As GLP-1 Drugs Go Mainstream,
Description
The phase 3 FLOW trial evaluated Ozempic in patients with T2DM and chronic kidney disease (CKD)
Both proteins (GLP-1 and VEGFA) share common pathways and most importantly interacts with cytoplasmatic Src kinase that controls a wide variety of signaling pathways leading to control of vessel tone through endothelial cell signaling
Cutaneous ocular Toxicol
The glucagon component is especially relevant for liver fat
